Fexofenadine in pediatrics: Oral tablet and suspension formulations

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 2, 2008, Pages 329-337

  Mansfield, Lyndon E ^a  

^a Texas Tech Regional Health Science Center   (United States)

Author keywords

Allergic rhinitis; Children; Fexofenadine; Pediatric; Suspension formulation

Indexed keywords

ANTACID AGENT; ANTIHISTAMINIC AGENT; ERYTHROMYCIN; FEXOFENADINE; KETOCONAZOLE; PLACEBO; PROMETHAZINE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; APPLE JUICE; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BIOEQUIVALENCE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHRONIC URTICARIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; FRUIT JUICE; GASTROINTESTINAL PAIN; GRAPEFRUIT JUICE; HAY FEVER; HUMAN; INFECTION; INJURY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORANGE JUICE; OTALGIA; OTITIS MEDIA; PAIN; PEDIATRICS; PHARMACODYNAMICS; PHARYNGITIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; SUSPENSION; SYMPTOM; TABLET FORMULATION; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DEGLUTITION; HUMANS; INFANT; RHINITIS, ALLERGIC, SEASONAL; SUSPENSIONS; TABLETS; TERFENADINE;

EID: 39049151178     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.2.329     Document Type: Article

References (47)

1. Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895-901
2. Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81:463-8
3. Berger WE. Allergic rhinitis in children: diagnosis and management strategies. Paediatr Drugs 2004;6:233-50
4. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45-53
5. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105:S622-7
6. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-13
7. Skoner DP. Complications of allergic rhinitis. J Allergy Clin Immunol 2000;105:S605-9
8. Slavin RG. Complications of allergic rhinitis: implications for sinusitis and asthma. J Allergy Clin Immunol 1998;101:S357-60
9. Polosa R, Al-Delaimy WK, Russo C, et al. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005;6:153
10. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674-6
11. Milgrom H, Bender B. Adverse effects of medications for rhinitis. Ann Allergy Asthma Immunol 1997;78:439-44; quiz 445-6.
12. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111:S835-42
13. Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005;84:163-8
14. Howarth P. The choice of an H1-antihistamine for the 21st century. Clin Exp All Rev 2002;2:1-8
15. Stokes J, Fenstad E, Casale TB. Managing impairment in patients with allergic rhinitis. Allergy Asthma Proc 2006;27:12-6
16. Sanofi-Aventis. Allergra Prescribing Information. http://products.sanofi-aventis.us/allegra/allegra.html; 2007
17. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8
18. Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998;19:135-41
19. Finn AF Jr, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071-8
20. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84:517-22
21. Graft DF, Bernstein DI, Goldsobel A, et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:22-6
22. Wahn U, Meltzer EO, Finn AF Jr, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003;111:763-9
23. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-60
24. Krishna R, Krishnaswami S, Kittner B, et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004;25:373-87
25. Simons FE, Bergman JN, Watson WT, Simons KJ. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996;98:1062-4
26. Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinids in children 2 to 5 years old. Ann Allergy Asthma Immunol 2007;99:358-63
27. Hampel FC, Kittner B, Van Bavel J. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy, Asthma Immunol (In Press)
28. Morrison D, Sahasranaman S. The 30 mg dose of fexofenadine HCl 6 mg/ml suspension is bioequivalent to the marketed 30 mg tablet in healthy adult subjects under fasted conditions: a randomized, crossover, open-label study. Presented at AAAAI. 2007 (Abstract 564)
29. Grubbe R, Nayak A, Kittner B, Segal N. The pharmacokinetics, safety and tolerability of fexofenadine HCl 6 mg/ml suspension in children with allergic rhinitis: a multicenter, open-label, single-dose study. Presented at AAAAI. 2007 (Abstract 563).
30. Triggiani M, Gentile M, Secondo A, et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001;166:4083-91
31. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601-7
32. Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20
33. Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999;36:329-52
34. Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol 2003; 90:629-34
35. Purohit A, N'gom AS, Deslandes B, et al. Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol 2004;93:562-7
36. Grant JA, Riethuisen JM, Moulaert B, Devos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 h in healthy male subjects. Ann Allergy Asthma Immunol 2002;88:190-7
37. White M, Rothrock S, Meeves S, et al. Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare. Allergy Asthma Proc 2005;26:221-8
38. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999;29(Suppl 3): 163-70; discussion 171-3.
39. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14
40. Robbins DK, Casdes MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19:455-63
41. Lippert C, Ling J, Brown P. Mass balance and pharmacokinetics of fexofenadine HCl in healthy male volunteers. Pharm Res 1995;12:390
42. Ngamphaiboon J, Direkwattanachai C, Visitsunthorn N, et al. The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. Asian Pac J Allergy Immunol 2005;23:169-74
43. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32:133-9
44. Ridout F, Hindmarch I. The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. Ann Allergy Asthma Immunol 2003;90:404-10
45. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29(Suppl 3):133-42
46. Morgan MM, Khan DA, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 2005;39:2056-64
47. Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006;66:2309-19